Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $110000.0.

  • Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) fell 1538.46% to $110000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $463000.0, marking a year-over-year decrease of 1834.22%. This contributed to the annual value of $540000.0 for FY2024, which is 344.83% up from last year.
  • Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) amounted to $110000.0 in Q3 2025, which was down 1538.46% from $113000.0 recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Depreciation & Amortization (CF) high stood at $150000.0 for Q4 2023, and its period low was $25000.0 during Q2 2021.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) had a median value of $113000.0 in 2025 and averaged $95894.7.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) tumbled by 6093.75% in 2021 and then skyrocketed by 34062.5% in 2022.
  • Viridian Therapeutics, Inc.\DE's Depreciation & Amortization (CF) (Quarter) stood at $32000.0 in 2021, then skyrocketed by 340.62% to $141000.0 in 2022, then rose by 6.38% to $150000.0 in 2023, then dropped by 18.0% to $123000.0 in 2024, then decreased by 10.57% to $110000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $110000.0 for Q3 2025, versus $113000.0 for Q2 2025 and $117000.0 for Q1 2025.